Media & Resources

Report released at AIDS 2012 calls for sustained funding of HIV prevention research to achieve our collective vision of zero new HIV infections Washington DC (23 July 2012) – A decade of unprecedented investment in HIV prevention research has led to major scientific breakthroughs in vaccines, microbicides, voluntary medical male circumcision, treatment as prevention and…

Partnership to accelerate development of vaccines against the world’s deadliest infectious diseases, tuberculosis and HIV July 17, 2012—New York, New York and Rockville, MD— Aeras and the International AIDS Vaccine Initiative (IAVI) are pleased to announce the expansion of their existing partnership through a formal collaboration agreement. The two nonprofit organizations, which focus on tuberculosis (TB)…

New York, July 16, 2012—The International AIDS Vaccine Initiative applauds the U.S. Food and Drug Administration (FDA) for its decision to approve the combination anti-retroviral (ARV) drug Truvada for the prevention of HIV. More than 7,400 individuals worldwide are newly infected with HIV every day, and several studies have shown that ARV-based pre-exposure prophylaxis (PrEP)…

New York, July 11, 2012—The International AIDS Vaccine Initiative warmly congratulates The Scripps Research Institute and Duke University for winning major grants from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Disease (NIAID) to support the design and development of preventive HIV vaccines. The Center for HIV/AIDS Vaccine Immunology & Immunogen…

NEW YORK, May 30, 2012—The International AIDS Vaccine Initiative (IAVI) is pleased to announce the appointment of Louis Schwartz as Chief Financial Officer. In this role, Schwartz will oversee the financial operations of the organization, working closely with IAVI’s Senior Management Team and Board of Directors. He will also lead IAVI’s Finance & Administration team,…

A Phase I clinical trial comparing a daily regimen of antiretroviral pre-exposure prophylaxis (PrEP) with an intermittent regimen found that rates of adherence to intermittent dosing regimens were lower than adherence to daily dosing.  The study is the first ever to report data on intermittent antiretroviral PrEP use in humans.  The results from this trial…

New Data Illustrates Potential Impact of AIDS Vaccine May 18, 2012—Today, on World AIDS Vaccine Day, we are reminded that AIDS continues to devastate the lives of millions of people across the globe, orphaning children, ravaging communities and disrupting economies. The effort to end the AIDS pandemic requires truly global commitment, and we must continuously…

NEW YORK, NY, GAITHERSBURG, MD, and ATHENS, GA, May 9, 2012 – The International AIDS Vaccine Initiative (IAVI), GlycoMimetics, Inc. (GMI), and Glycosensors and Diagnostics, LLC (G&D) today announced a collaboration to develop an AIDS vaccine using novel compounds that mimic carbohydrates, called glycomimetics.  The project will be funded by IAVI’s Innovation Fund, a program…